What Is Elosulfase Alfa? Definition and What Research Reports

Definition

Elosulfase alfa (development code BMN 110) is a recombinant human N-acetylgalactosamine-6-sulfatase (GALNS), a lysosomal enzyme manufactured in cultured mammalian cells and administered by intravenous infusion as an enzyme replacement therapy for mucopolysaccharidosis type IVA, also called Morquio A syndrome. In that inherited disorder, deficient GALNS activity prevents normal breakdown of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate, which accumulate in bone, cartilage, heart valves and other tissues. Elosulfase alfa is intended to supply a functional copy of the missing enzyme; published reviews described it as an approved enzyme replacement therapy for Morquio A syndrome and summarised the trial programme behind that approval (PMID 25200032, PMID 27855521). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis or treatment.

What Class of Molecule Is It, and Where Does It Come From?

Elosulfase alfa is a large, glycosylated protein — an enzyme — rather than a short synthetic peptide. It is produced by recombinant DNA technology in a mammalian cell line, which allows the mannose-6-phosphate glycan tags required for cellular uptake to be added during production. Those tags let circulating enzyme bind cation-independent mannose-6-phosphate receptors on cell surfaces and be trafficked into lysosomes, where the missing sulfatase activity is needed. Reviews of the compound described this receptor-mediated uptake pathway as the basis of its mechanism in Morquio A syndrome (PMID 27366102, PMID 35046639).

How the Term Is Used in Peptide and Protein Literature

In peptide-adjacent research writing, elosulfase alfa is normally cited as a worked example rather than as a peptide in the narrow sense. Three uses of the term recur:

• As a biologic comparator. Discussions of peptide and protein therapeutics often contrast small synthetic peptides, which can sometimes be chemically manufactured and are cleared quickly, with recombinant enzymes such as elosulfase alfa, which require cell-based expression and post-translational glycosylation.
• As an example of targeted delivery. Literature on receptor-mediated uptake uses the mannose-6-phosphate tagging of enzyme replacement therapies to illustrate how a large protein reaches an intracellular compartment (PMID 27366102).
• As an immunogenicity case study. Because recombinant enzymes are given to patients who may have little or no native protein, anti-drug antibody responses are common, and the elosulfase alfa programme reported detailed antibody data (PMID 25487082).

Naming note: the "-ase" stem signals an enzyme, and the "alfa" suffix denotes a specific glycosylation variant of a recombinant protein, a convention shared with other biologics.

What the Published Literature Reports

Controlled and long-term clinical studies

The pivotal development programme evaluated intravenous elosulfase alfa at 2.0 mg/kg administered weekly in patients with Morquio A syndrome, a regimen described across drug reviews of the compound (PMID 25200032, PMID 27855521). A randomised, double-blind pilot study compared two different dose levels of elosulfase alfa and reported on safety and physiological measures in treated patients (PMID 26069231). A long-term analysis of endurance and safety in the extension setting reported endurance outcomes, including walk-test performance, in patients who continued enzyme replacement therapy beyond the controlled phase (PMID 27380995).

A 2022 systematic review and meta-analysis pooled intravenous elosulfase alfa studies in mucopolysaccharidosis type IVA and reported improvements in endurance measures and reductions in urinary keratan sulfate relative to baseline or comparator conditions (PMID 36013287). Researchers analysing a Managed Access Agreement cohort in England reported clinical and patient-reported outcomes during long-term treatment, adding real-world observational data to the trial record (PMID 33478511).

Pharmacokinetics and pharmacodynamics

A dedicated pharmacokinetic and pharmacodynamic evaluation characterised plasma exposure to elosulfase alfa after infusion in patients with Morquio A syndrome and examined the relationship between exposure and urinary keratan sulfate, the biochemical marker used throughout the programme (PMID 25234648). Reviews summarising the clinical pharmacology noted that the enzyme is cleared rapidly from circulation, consistent with receptor-mediated tissue uptake (PMID 27855521).

Younger patients

A study in pediatric patients with Morquio A syndrome younger than 5 years reported on safety and clinical activity of elosulfase alfa in that age group, which had not been included in the original controlled trial population (PMID 26331768).

Immunogenicity and Tolerability: What Studies Report

Immunogenicity was a prominent endpoint in this programme. In the phase III MOR-004 trial, researchers reported that treated patients developed anti-drug antibodies, and the analysis also examined neutralising antibodies capable of interfering with enzyme uptake and their relationship to clinical and biochemical outcomes (PMID 25487082). The MOR-005 phase III extension reported long-term immunogenicity data over continued treatment, extending the antibody follow-up beyond the controlled period (PMID 27955919).

On tolerability, drug reviews of elosulfase alfa described infusion-associated reactions — including hypersensitivity-type events — as the adverse events most consistently associated with treatment, alongside more general events such as vomiting, headache and pyrexia in trial populations (PMID 25200032, PMID 35046639). The long-term endurance and safety analysis reported safety findings across extended exposure (PMID 27380995), and the randomised dose-comparison pilot reported safety observations at the dose levels it examined (PMID 26069231). Nothing on this page describes how any of these findings should be applied; that is a matter for treating clinicians.

Common Points of Confusion

• It is not a research peptide. Elosulfase alfa is a prescription biologic evaluated in regulated clinical trials, not a research-use-only compound sold for laboratory investigation. Its literature sits in clinical genetics and metabolic medicine.
• It replaces an enzyme; it does not correct the gene. Reviews framed enzyme replacement therapy as supplying functional enzyme to cells rather than altering the underlying GALNS genotype (PMID 27366102).
• Keratan sulfate is a marker, not an outcome by itself. Published analyses reported urinary keratan sulfate alongside functional endpoints such as walk tests rather than in isolation (PMID 36013287).
• "Alfa" is a glycoform designation. It distinguishes a specific recombinant version of a protein and does not imply a strength or dose.

Summary of the Entry

Elosulfase alfa is defined as a recombinant human GALNS enzyme delivered intravenously in mucopolysaccharidosis type IVA. It belongs to the recombinant protein and enzyme-replacement class rather than the short-peptide class, and it is produced in mammalian cell culture with mannose-6-phosphate glycans that support lysosomal delivery. The published record includes controlled trials, an extension programme, pharmacokinetic work, pediatric data, real-world managed-access outcomes and a meta-analysis, with immunogenicity and infusion-associated reactions documented as recurring safety themes (PMID 25487082, PMID 25200032). Again, this entry is educational and is not medical advice.

References

• Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome) (Expert Review of Clinical Pharmacology, 2016)
• Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome) (BioDrugs, 2014)
• Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome (Drug Design, Development and Therapy, 2022)
• Role of elosulfase alfa in mucopolysaccharidosis IVA (The Application of Clinical Genetics, 2016)
• Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis (Journal of Personalized Medicine, 2022)
• Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England (Orphanet Journal of Rare Diseases, 2021)
• Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome (Molecular Genetics and Metabolism, 2016)
• Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome (Clinical Pharmacokinetics, 2014)
• Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial (Clinical Therapeutics, 2015)
• Safety and physiological effects of two different doses of elosulfase alfa in patients with Morquio A syndrome: A randomized, double-blind, pilot study (American Journal of Medical Genetics Part A, 2015)
• Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study (Clinical Therapeutics, 2017)
• Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y (Pediatric Research, 2015)